Decision/Conclude agreement
Proposed

方達控股目標業務出售予Charles River Laboratories

方達控股的生物分析及DMPK等目標業務將以約4.7億美元初步估值出售予Charles River Laboratories,作為其私有化及業務分拆的一部分,讓泰格醫藥剝離非核心業務並聚焦臨床CRO服務。

Trajectories

Sign-in readers can mine up to three arcs for this record.

Sign in to get trajectories

Actors and targets

Targets Charles River Laboratoriesactor生物分析及藥物代謝動力學(DMPK)等目標業務item

Source

生物分析及藥物代謝動力學(DMPK)等目標業務將出售予Charles River Laboratories,初步估值約4.7億美元
stockintelligencenews · Telegram Open post

Not established

  • Announcement date
  • Expected closing date
  • Transaction currency of payment
  • Financing structure

Extracted detail

Related decisions

Same kind only, ranked by embedding similarity to this record.